Type 1 diabetes (T1D) is a T-cell-mediated autoimmune disease resulting in islet b-cell destruction, hypoinsulinaemia and severely altered glucose homeostasis. Although the mechanisms that initiate T1D still remain elusive, a breakdown of immune tolerance between effector T-cells (T eff ) and regulatory T-cells (T reg ) is considered to be the crucial component leading to autoimmunity. As such, strategies have been developed to boost the number and/or function of T reg in the hope of specifically hampering the pathogenic T eff activity. In this review, we will summarize the current understanding of biomarkers and functions of both forkhead box protein 3 (FoxP3) + T reg and type 1 regulatory T (Tr1) cells in health and in T1D, examine the outcome of experimental therapies in both animal models and humans via manipulation of T reg responses and also provide an outlook on the potential of T reg -based immunotherapies in the prevention and treatment of this disease. Discussed immunotherapies include adoptive transfer of ex-vivo expanded FoxP3 + T reg , manipulation of T reg cells via the interleukin (IL)-2/IL-2R pathway and induction of T reg by tolerogenic peptides, tolerogenic dendritic cells or altered gut microbiota.
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Type 1 diabetes (T1D) is a T-cell-mediated autoimmune disease resulting in islet b-cell destruction, hypoinsulinaemia and severely altered glucose homeostasis. Although the mechanisms that initiate T1D still remain elusive, a breakdown of immune tolerance between effector T-cells (T eff ) and regulatory T-cells (T reg ) is considered to be the crucial component leading to autoimmunity. As such, strategies have been developed to boost the number and/or function of T reg in the hope of specifically hampering the pathogenic T eff activity. In this review, we will summarize the current understanding of biomarkers and functions of both forkhead box protein 3 (FoxP3) + T reg and type 1 regulatory T (Tr1) cells in health and in T1D, examine the outcome of experimental therapies in both animal models and humans via manipulation of T reg responses and also provide an outlook on the potential of T reg -based immunotherapies in the prevention and treatment of this disease. Discussed immunotherapies include adoptive transfer of ex-vivo expanded FoxP3 + T reg , manipulation of T reg cells via the interleukin (IL)-2/IL-2R pathway and induction of T reg by tolerogenic peptides, tolerogenic dendritic cells or altered gut microbiota.
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Pathogenesis of T1D and the role of T lymphocytes
Type 1 diabetes (T1D) is a chronic autoimmune disease resulting from progressive destruction of pancreatic bcells (reviewed in Katsarou et al. 1 ). It normally develops in two distinct phases: insulitis, when a mixed population of immune cells invades the islets, and clinical diabetes, when most b-cells have been destroyed and there is no longer sufficient insulin to regulate blood glucose, resulting in hyperglycaemia. While the aetiology of this disease remains unclear, genetic, epigenetic and environmental factors are all considered to play an important role. At least 20 different chromosomal regions have been linked to T1D susceptibility in humans, 2 including several genes involved in immune regulation, such as human leucocyte antigen (HLA) class II alleles, cytotoxic T lymphocyte antigen-4 (CTLA4) and interleukin (IL)-2 receptor alpha (IL2RA). In addition, viral infections, geographical locations, lifestyle traits and microbiota composition can also influence the disease incidence. 3 The pathology of T1D indicates the involvement of both autoantibodies and T-cells. However, autoantibodies per se do not substantially contribute to the initiation and/or perpetuation of the autoimmune process, except for their role as serological markers to identify 'high-risk' individuals. 4 In contrast, the imbalance between CD4 + effector T-cells (T eff ) and regulatory T-cells (T reg ) may trigger disease development. 5 It has been clear that T eff can promote b-cell death either by providing 'help' to CD8 + T-cells that can mediate perforin and/or Fas-based cytolytic killing or by secreting inflammatory cytokines such as interferon (IFN)-c, tumour necrosis factor (TNF)-a, IL-1 and other soluble mediators, such as nitric oxide (NO). As a suppressive cell type, T reg conduct their functions in an opposing manner by inhibiting the proliferation/differentiation of T eff and cytokines/mediators they secrete. Given their immunoregulatory nature, T reg are thought to play an indispensable role in controlling unwanted immune responses and maintaining immunological tolerance. In fact, absence or defective function of T reg has been correlated with autoimmunity such as autoimmune diabetes in humans.
T reg and their association in T1D
There are two main types of T reg cells: FoxP3 + T reg , that are mainly selected in the thymus but can also be induced in the periphery mainly through the action of TGF-b and IL-2 in the context of T-cell receptor (TCR) stimulation by antigens, 6, 7 and IL-10-secreting type 1 regulatory T (Tr1) cells, that are exclusively induced in the periphery. Both T reg cell types have been comprehensively reviewed elsewhere. 8, 9 Therefore, we will focus only on their association with T1D and particular phenotypes and functions ( Fig. 1 ) that have been linked with targeted therapies discussed later in this review.
FoxP3
+ T reg FoxP3 + T reg are the best-defined T reg population. They were first identified in mice, and express CD25 on their surface. 10 However, CD25 is of limited use as a marker in humans due to its wide range of expression in human CD4 + T-cells. 11 To search for more specific markers to enrich human T-cells with regulatory function, L-selectin (CD62L), cytotoxic T lymphocyte antigen-1 (CTLA-4) and glucocorticoid-induced tumour-necrosis factor receptor (GITR) have been identified. 12 Nevertheless, like CD25, expression of these molecules is not restricted to FoxP3 + T reg and they can also be expressed on activated T-cell subsets. The best current approach is to isolate CD4 + CD25 + CD127 À (IL-7 receptor-a chain) cells. This combination results in > 98% purity of FoxP3 + T reg with a significantly higher yield of cells compared with those isolated using other cell surface markers. 13, 14 To maintain development and functionality, the transcriptional factor FoxP3 seems to be crucial. Mutations in Foxp3 in mice and its orthologue in humans leads to a phenotype with severe autoimmune diseases, known as the scurfy mutation in mice 15 and immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) in humans. 16 Following studies in mice with deficiency in IL-2 and IL-2R subunits further demonstrated that IL-2 is a key cytokine required for the induction of FoxP3 expression, differentiation of FoxP3 + T reg in the thymus and their peripheral maintenance with suppressor ability. [17] [18] [19] IL-2 deprivation even causes loss of FoxP3 expression and the conversion of T reg into pathogenic T eff cells. 20 
+ T reg exert their suppressive function mainly in a cell contact-dependent manner. The interaction with antigen-presenting cells (APCs) such as dendritic cells (DCs) through surface-expressed inhibitory molecules, for example CTLA-4 and programmed death-1 ligand (PD-L1), can either exclude T eff from contact with DCs or alter the DC phenotype to turn them tolerogenic. While CTLA-4 or PD-L1 is only up-regulated in T eff upon activation, it is constitutively expressed in FoxP3 + T reg . CTLA-4 is considered to outcompete CD28 in the binding of costimulatory molecules CD80 and CD86 in APCs, thus diminishing their capacity to activate T eff . 21 Moreover, CTLA-4 engagement can also induce DCs to produce the immunosuppressive molecule indoleamine 25 ), metabolic disruption via adenosine generated by ectoenzymes CD39 and CD73 26 and cytolysis in a granzyme B/ perforin-dependent manner. 27 The study of FoxP3 + T reg in T1D patients has yielded contradicting results. Some studies reported a lower frequency of FoxP3 + T reg [28] [29] [30] and/or defective suppressive function 31, 32 in patients with T1D, while others reported no differences. 33, 34 This discrepancy may be caused by the use of different markers to define FoxP3 + T reg populations, differences in the cohort of patients or the variability in experimental conditions.
Tr1 cells
Tr1 cells were originally described by the Roncarolo group. 35 These cells do not express high levels of CD25 or FoxP3, and are characterized by their unique cytokine production profile: they secrete high levels of IL-10 and TGF-b, low amounts of IFN-c and IL-2 and no IL-4. 9, 35 In 2013, the characteristic cell-surface markers, CD49b and lymphocyteactivation gene 3 (LAG-3), were identified for Tr1 in humans and mice. 36 This development provides a basis for further study of this T-cell subset and also facilitates in-vitro purification and in-vivo tracking. Although a number of transcription factors, 9 such as the cellular homologue of the avian virus oncogene musculoaponeurotic fibrosarcoma (cMaf), the aryl hydrocarbon receptor (AhR), interferon regulatory factor 4 (IRF4), the repressor of GATA binding protein 3 (ROG) and early growth response protein 2 (Egr-2), have been proposed as transcriptional biomarkers for Tr1, none of them is lineage-specific. Factors to differentiate Tr1 cells include IL-10-treated tolerogenic DCs, 37 IL-27 with or without TGF-b, 38 ,39 IL-10, 35 oral administration of autoantigens at a low concentration, 40 anti-CD3 monoclonal antibody (mAb) treatment [41] [42] [43] and certain species of dysbiotic gut microbiota. 43 Tr1 cells mainly mediate their suppression through their secreted cytokines, such as IL-10/TGF-b, which either directly suppress T eff cells 44 or indirectly inhibit the maturation of APCs by down-regulating the expression of major histocompatibility complex (MHC) class II and costimulatory molecules as well as inflammatory factors, and up-regulating a number of tolerogenic molecules, including immunoglobulin-like transcript (ILT)-2, 3 and 4 and the non-classical HLA-G. 37, 45 In the diabetes setting, newly diagnosed T1D patients and first-degree relatives appear to have fewer IL-10-secreting cells compared with healthy controls. 46, 47 This deficit in T reg is amplified by an increased T eff function, as reflected by increased antigen-specific IFN-c secretion. [46] [47] [48] Interestingly, in 63% of patients who received anti-CD3 immunotherapy, serum IL-10 levels were significantly increased and IL-10 expression was also induced in~10% of peripheral CD4 + T-cells on day 12 of drug treatment. 42, 49 Because anti-CD3 mAb therapy has demonstrated a modest success, elevation of Tr1 in periphery may contribute to the beneficial outcome of this treatment. In fact, both in-vitro and in-vivo mouse studies have suggested that Tr1 can directly suppress diabetogenic T-cells and block diabetes development in the adoptive transfer model. 40, 43, 50, 51 T reg -based immunotherapy in autoimmune diabetes: advances and future developments
To correct the defects in T reg observed in T1D, strategies to increase T reg cell number and/or function have been viewed as potential therapeutic approaches. During recent past years, much progress has already been made in animal models and human clinical trials, which demonstrated that ex-vivo or in-vivo induction of T reg are feasible and might be highly advantageous in the treatment of this autoimmune disease. Murine studies and current clinical developments in T reg therapy have been summarized in Table 1 . In the following section, we will analyse published evidence to understand more clearly how immune tolerance can be regenerated. 52 This work suggested that a similar approach could be applied to humans -that is, FoxP3 + T reg could be isolated from a patient, and then enriched, expanded and reinfused. However, the clinical testing process has been hampered by a few factors, such as lack of specific surface markers to isolate FoxP3 + T reg from human peripheral blood, the anergic and unfavourable ex-vivo expansion properties associated with these cells and potential T eff cell contamination. To overcome these limitations, much effort has been made. For example, CD127 was identified to be a reliable surface marker that, in combination with CD4 and CD25, selectively distinguishes FoxP3 + T reg from conventional T eff cells in humans. 13 Several T reg expansion protocols have also been developed to expand FoxP3 + T reg to the desired number. Studies reported that these cells could be expanded hundreds or thousands-fold with more potent suppressive activity via anti-CD3/CD28 stimulation in the presence of high doses of IL-2 53, 54 K562 cells, an artificial APC cell line engineered to express CD86 and the high affinity Fc receptor (CD64). 55 In addition, adding rapamycin to the expansion culture significantly increased the purity of FoxP3 + T reg and reduced the risk of undesired T eff proliferation. 56, 57 A recent clinical study conducted with ex vivoexpanded FoxP3 + T reg has yielded encouraging results in children with recent-onset T1D. 58, 59 Patients treated with autologous expanded CD4 + CD25 + CD127 low/À cells have shown improved b-cell function, higher fasting C-peptide level and reduced exogenous insulin use in the majority of the patients, with two patients remaining totally insulin-free. Although these expanded FoxP3 + T reg maintained their phenotype and displayed enhanced suppressive functions in vitro due to elevated signal transducer and activation of transcription-5 (STAT-5) phosphorylation in response to IL-2, 60 they were short-lived in vivo after adoptive transfer. In one study, the cell numbers reduced to baseline at 2 years after the first infusion, 59 and in another, only~25% of transferred T reg persisted in the circulation a year later. 60 Because the survival and function of FoxP3 + T reg highly depends upon IL-2 18 and sudden deprivation of this cytokine upon releasing cells in vivo may account for this decline, 20 combining FoxP3 + T reg with cytokine therapy such as IL-2 might be beneficial. Therefore, Bluestone and colleagues have started another clinical trial to assess the safety of FoxP3 + T reg + exogenous IL-2 and its effect on the T reg viability (NCT02772679). It is also noteworthy that inflammatory mediators secreted under T1D environment such as TNF-a, IL-1b and IL-6 promote T eff responses at the expense of T reg . Neutralization of these mediators might further help to maintain the functional integrity of adoptive-transferred FoxP3 + T reg and enhance their halflife and the consequent therapeutic efficacy. 61 
Manipulating FoxP3
+ T reg in vivo via the IL-2/IL-2R pathway
FoxP3
+ T reg constitutively expresses high-affinity IL-2Ra, which enables them to respond efficiently to this cytokine even at a low concentration. 62 Thus, administration of low-dose IL-2 may preferentially expand this type of T reg over T eff cells. Results in animal models 63, 64 have demonstrated that low-dose IL-2 increased the number of FoxP3 + T reg , suppressed INF-c production by pancreasinfiltrating T-cells and protected mice from developing diabetes. Most importantly, by performing transcriptome analysis, the studies also showed that low-dose IL-2 exerted much greater influence on genes expressed in T reg than those of T eff , suggesting that non-specific activation of pathogenic T eff was less likely. The therapeutic concept of using low-dose IL-2 is further supported by data in human clinical studies. Two completed Phase I/II clinical trials [65] [66] [67] have indicated a good safety profile and IL-2 dose-dependent increase of FoxP3 + T reg in patients with T1D.
Although the above-mentioned primary studies pave the way for this new therapy to be potentially applied, such intervention warrants continued and comprehensive exploration. Namely, can low-dose IL-2-induced FoxP3 + T reg effectively suppress the pathogenic immune response and restore a proper T reg /T eff balance? Could an excessive dose of IL-2 alters metabolic processes and predispose patients to infections and cancers due to prolonged immunosuppression? To further test the therapeutic value and impact of IL-2, three dose-finding or efficacy trials (NCT01862120, NCT02265809, NCT02411253) are being undertaken to investigate the optimal dose and frequency of IL-2 administration and if this treatment could block the autoimmune destruction of insulin-producing b-cells in patients.
Interestingly, apart from injecting IL-2 as a cytokine, one emerging idea for selectively modulating the effects 68 Moreover, advances in techniques for sitedirected mutagenesis and structure biology may also offer the possibility to genetically manipulate IL-2 binding and provide conformational analysis to fine-tune the activity of IL-2. Currently, modified versions of IL-2 and IL-2 complexes are under development, which has become an active and prominent research area. We believe that increasingly diversified IL-2 partial agonists 69 will be produced in the future to promote the desirable actions while minimizing the deleterious actions.
Modification of DC function to promote T reg
That DCs play an important role in the induction and maintenance of self-tolerance has made them attractive targets for therapeutic intervention. 70 Three main strategies have been employed. These include adoptive transfer of particular DC subsets, 71, 72 in-vitro expansion of T reg with specific DCs 73, 74 and in-vivo DC targeting. Although the complexity of DC subsets and the plasticity of their function have made this a challenging objective, DCs with a so-called tolerogenic phenotype are thought to be most effective to promote the development of T reg and induce tolerance in the context of autoimmunity.
Tolerogenic DC can be induced by exposing to different cytokines, such as granulocyte-macrophage colonystimulating factor (GM-CSF), 75, 76 granulocyte colony-stimulating factor (G-CSF), 77 and IL-10 alone 78, 79 or in combination with TGF-b. 80, 81 Pharmacological mediators, including dexamethasone and vitamin D3 82, 83 or immunosuppressive drugs such as rapamycin (RAPA) 84, 85 can also modulate DC to induce FoxP3 + T reg . Alternatively, tolerogenic properties of DC can be generated both by exposure to CTLA-4 fusion protein [CTLA-4-immunoglobulin (Ig)], 86 or by genetic manipulation using antisense oligonucleotides to down-regulate the expression of costimulatory molecules. 72 A recent study compared the ability of several DC-conditioning regimens to induce suppressive T reg in the human system. The results have indicated that DC pretreated with IL-10 induced the most suppressive T reg , while TGF-b, RAPA and dexamethasone were less effective. 87 In general, the treatment of DC with these agents induces a semi-mature phenotype characterized by the reduced expression of MHC class II and costimulatory molecules (CD40, CD80, CD86), reduced inflammatory cytokine production (IL-1b, IL-6, TNF-a and most markedly IL-12) and the induction of tolerogenic molecules, such as IL-10 and IDO. 86, 88 By contrast, DCs induced by IL-10, termed DC10, display a mature myeloid phenotype (CD80 + CD86 + ), secrete high levels of IL-10 and express tolerogenic markers such as ILT-2, 3, 4 and HLA-G. 37 Although IL-10-conditioned DCs are capable of inducing FoxP3 + T reg , 78 they are more potent inducers of Tr1 cells. 37 Among molecules that modulate DC function, several have been applied in clinical trials. During 2 years of costimulation with abatacept (CTLA-4-Ig), patients with recent-onset T1D showed a slow decline of b-cell function, lower HbA1c level and more endogenous insulin production. 89, 90 However, this treatment is reminiscent of the effects of anti-CD3 mAb. The main effect seems to be early after the initiation of the treatment, followed later by a decline in b-cell function parallel to that in the control group. As a consequence, abatacept is currently being tested for its role in preventing or delaying the development of diabetes in relatives at-risk for T1D (NCT01773707). Although pegylated G-CSF has not shown benefit as single treatment agent, 91 a combination of low-dose anti-thymocyte globulin (ATG), a potent immune-depleting agent and G-CSF increased the frequency of FoxP3 + T reg and preserved b-cell function in patients with established T1D. 92, 93 Nevertheless, because of the small sample size reported, validating the clinical result in a larger cohort is clearly necessary. In addition, an NIH-funded Phase II trial is being conducted to explore whether earlier intervention with ATG+G-CSF in subjects with recent-onset T1D (duration < 4 months) may offer improved efficacy (NCT02215200).
As DC10 efficiently promotes the differentiation of type 1 regulatory T-cells, this DC subset has been utilized to expand Tr1 ex vivo. Adoptive transfer of DC10-expanded Tr1 largely reduced donor-versus-host reactivity in patients affected by haematological malignancies who underwent T-cell-depleted haploidentical haematopoietic stem cell transplantation.
94 DC10-expanded Tr1 cells have also been selected to be a part of the ONE Study to assess the safety, clinical practicality and therapeutic efficacy in kidney transplanted recipients. 95, 96 Despite the limited use of Tr1 in present clinical studies, with increased recognition of their importance in controlling T1D and other autoimmune and inflammatory diseases, 41, 43, 97 a broader use of Tr1 cells might be forthcoming.
T reg induced by tolerogenic peptides
Studies performed in both rodents and humans suggest the notion that vaccination of short immunogenic peptides of disease-related autoantigens may stimulate tolerogenic mechanisms and delay or prevent autoimmune diabetes. Although it is still not clear which antigen(s) should be selected to build the vaccine, epitopes of insulin/proinsulin B9-23 (the 9-23 amino acid region of the insulin B chain) [98] [99] [100] and C19-A3 (the proinsulin C-A chain junction) [101] [102] [103] are the most considered antigens and have been examined in diverse administration routes, including intrathymic, intramuscular, intradermal, subcutaneous and intranasal. These peptides, after being delivered in vivo, were capable of generating FoxP3 + T reg and/ or antigen-specific IL-10-producing T-cells. In a recently reported clinical trial, treatment of newly diagnosed (< 100 days) T1D patients with DR*04:01-restricted proinsulin peptide C19-A3 102 has been proven safe and well tolerated. C-peptide decline and increased insulin use were not seen in the treated subjects during 12 months. To enhance the immune reaction and increase the lifespan of C19-A3 peptides in blood -and probably in other tissues -another Phase I trial has been initiated to test the feasibility, safety and immune responses of this proinsulin peptide coupled to gold nanoparticles (NCT02837094).
When attempting peptide-based immunotherapy, past experience also tells us that the following elements will need to be considered. First, the positive interpretations need to be balanced by other reported failures and robust and reproducible data need to be demonstrated. For example, administration of mimetope B12-23-R22E (the arginine residue R22 in the natural peptide replaced by glutamic acid) has shown contradictory results by either protecting 104 or accelerating the disease onset. 105 Secondly, while the goal of peptide administration is to induce T reg and inhibit specific autoimmune responses, the data show that, depending on the peptide used, one may also induce undesired proinflammatory T helper cells and cytotoxic T lymphocytes (CTL), both of which are capable of mediating b-cell damage. A notable example is B24-C36 (the proinsulin B-C chain junction) peptide, which can induce both regulatory CD4 + and cytotoxic CD8 + T-cell responses. 106 Taking all these into consideration, more mechanistic studies are required to gain an improved understanding of how efficient and stable T reg can be induced in the setting of T1D and how CTL epitopes in the vaccine peptides could be avoided or disabled to limit any risk of disease exacerbation. In our opinion, mouse strains expressing human class II and class I molecules that associated with T1D susceptibility are extremely useful. Such humanized mouse models could offer researchers the opportunity to test binding predictions, antigen dose and route of administration; provide in-vivo readout of the responses induced by a given peptide; and screen or guide the choice of peptides for future prevention trials.
Alteration of gut microbiota to induce T reg
The role of the intestinal microbiome in autoimmunity has garnered significant attention, with evidence from both mouse and human studies suggesting that defective development and/or alteration of healthy microbiota may result in abnormal immunoregulation that enables diabetes development. 107 A study conducted in four Finnish children further suggests that these changes seem to emerge after the appearance of autoantibodies, implying that the intestinal microbiota might be involved in the progression from b-cell autoimmunity to clinical disease, rather than in the initiation of the disease process. 108 Therefore, a number of longitudinal cohort studies [The Environmental Determinants of Diabetes in the Young (TEDDY), diabetic and autoimmune illness prophylactics (DIABIMMUNE) and Environmental Determinants of Islet Autoimmunity (ENDIA)] have been designed.
Results obtained from these studies should provide us with a clearer understanding of how environmental factors such as diet, hygiene and antibiotic usage affect the composition of the gut microbiome and how these alterations are associated with disease development. It has also been demonstrated that richness of certain bacteria may be the key factor to dampen the autoimmune responses. Oral administration of a mixture of different strains of viable lyophilized probiotic bacteria in early diabetic NOD mice, including Bifidobacteria, Lactobacilli and Streptococcus salivarius, induced IL-10-producing cells in gut-associated lymphoid tissue and prevented islet destruction and the onset of clinical signs of diabetes. 109 In a recent study, we also found that intestinal Tr1 were significantly induced in NOD mice after being colonized with microbiota from dysbiotic mice. These intestine-generated regulatory T-cells have the ability to migrate into the periphery and other organs to suppress diabetogenic T-cells. 43 In addition, suppression by FoxP3 + T reg may also be an underlying mechanism of how gut microbes could help to protect from this disease. Compared with specific pathogen-free (SPF) NOD mice, mice housed in germ-free (GF) conditions had accelerated insulitis with reduced FoxP3 + T reg . 110 Polysaccharide A (PSA) from Bacterioides fragilis, a common human commensal, is capable of inducing FoxP3 expression in previous FoxP3 À cells and enhance T reg suppressive activity. 111, 112 Bacteria can also modulate the T reg compartment by synthethizing particular metabolites. Notably, butyrate, a short-chain fatty acid, can induce the differentiation of FoxP3 + T reg in the gut from naive T-cells and increase T reg suppressive function. [113] [114] [115] Taken together, this evidence suggests that strategies targeting mucosal tissue to boost Tr1 or FoxP3 + T reg could represent a means to affect the natural history of autoimmune diabetes.
Interestingly, Bifidobacteria and Lactobacillus species are widely used in the food industry for production of yogurt and cheese, which are thought to be beneficial in reducing the risk of diabetes. By contrast, early exposure to a particular diet, such as cows' milk, gluten and other cereal components may trigger or promote autoimmune reactivity. 116 From this viewpoint, diet, which includes various antigens and also has an impact on gut microbiota, is critically important in T1D management. Manipulating diet to boost protective immune responses might be a good way to modify disease incidence. In a recent paper, a specialized fibre-rich diet has shown promise to protect against T1D. 117 This diet, after being broken down by microbiota in the large intestine, yielded high amounts of the short-chain fatty acids such as acetate and butyrate, which promote the frequency and function of FoxP3 + T reg and provide robust protection from antiislet-autoimmunity. This finding demonstrates the feasibility of early dietary interventions in T1D. However, before moving into human clinical trials, the effectiveness of treating human disease with medicinal foods remains unclear.
Conclusion and outlook
In the evolving field of T-cell biology, it is beginning to be recognized that FoxP3
+ T reg and Tr1 may have different roles to control diabetes. We and others have shown environmental factors such as gut microbiota can induce Tr1, while FoxP3 + T reg are primarily generated in the thymus. Therefore, it is reasonable to hypothesize that although both cell types serve to patrol in the steady state to regulate pathogenic immune responses, FoxP3
+ T reg and Tr1 may, respectively, represent intrinsic and extrinsic regulatory mechanism for disease protection. Moreover, in a study performed by Yao et al., 118 the authors found that Tr1, but not FoxP3 + T reg , suppress inflammasome Nlrp3 activation and IL-1b production. Interestingly, NOD mice deficient in Nlrp3 were protected from T1D 119 and IL-1b blockade has shown a synergistic protective effect when combined with anti-CD3 therapy in a mouse model. 120 All this evidence suggests that Tr1 cells may have specific therapeutic advantages that are not shared by FoxP3 + T reg . In addition, Tr1 may also serve as an immunological biomarker to distinguish the populations that might be at high risk for developing disease and predict the treatment outcome. Sanda et al. found that higher FoxP3 expression in T-cells at diagnosis predicted worse future glycaemic control, while higher mean numbers of IL-10 + T-cells were associated with better future glucose control, as measured by HbA1C. 121 The clinical trial of using anti-CD28 antibody underscores the danger of injecting agents that exert broad effects in modulating T-cell activity in vivo. 122 Therefore, current strategies have been designed to selectively target specific T-cell subsets (e.g. T reg ). Although both in-vitro and in-vivo modulation of T reg (Fig. 2) have shown some promise in early trials of treating autoimmune diabetes, none of them has induced long-lasting b-cell protection in humans. The reasons for this lack of success are unclear, but the efficacy of T reg immunotherapy could be influenced by several factors. First, as T reg therapy appears to be more effective in children within 2 months of diagnosis 58 than in adults diagnosed within 14-104 weeks, (DPP-IV) inhibitors. 123, 124 Secondly, if the cause of T1D is due to the increased resistance of T eff to T reg suppression, 125, 126 specific depletion of T effs with immunomodulatory drugs such as alefacept should be applied to shift the T eff /T reg balance. 127, 128 Alefacept is a human lymphocyte function-associated antigen 3 (LFA-3)/IgG1 fusion protein that interferes with the interaction between APCs and CD2 on the T-cell membrane, thus inhibiting T-cell activation.
As multiple aspects are involved in the aetiopathogenesis of T1D, including inflammation and innate immunity, classical adaptive immunity and vulnerable b-cells, a potential future strategy might involve numerous combinations, with each of them having demonstrated beneficial effects in animal models and safety in patients.
